Five Questions to Ask About Drug Risk | Resources
Biol Blood Marrow Transplant. 2010 Apr;16(4):443-68. Epub 2010
The role of cytotoxic therapy with hematopoietic stem cell
transplantation in the treatment of follicular lymphoma:
an evidence-based review.
Oliansky DM, Gordon LI, King J, Laport G, Leonard JP, McLaughlin
P, Soiffer RJ, van Besien KW, Werner M, Jones RB, McCarthy PL Jr,
Roswell Park Cancer Institute, Elm and Carlton Streets, Buffalo, NY
Clinical research examining the role of hematopoietic stem cell
transplantation (SCT) in the therapy of follicular non-Hodgkin
lymphoma in adults is presented and critically evaluated in this
systematic evidence-based review.
Specific criteria were used for searching the published literature
and for grading the quality and strength of the evidence and the
strength of the treatment recommendations.
Treatment recommendations reached unanimously by a panel of
follicular lymphoma experts are:
(1) autologous SCT is recommended as salvage therapy based on
pre-rituximab data, with a significant improvement in overall
survival (OS) and progression-free (PFS) survival;
(2) autologous SCT is not recommended as first-line treatment for
most patients because of no significant improvement in OS;
(3) autologous SCT is recommended for transformed follicular
(4) reduced intensity conditioning before allogeneic SCT appears to
be an acceptable alternative to myeloablative regimens;
(5) an HLA-matched unrelated donor appears to be as effective an HLA-matched
related donor for reduced intensity conditioning allogeneic SCT.
There are insufficient data to make a recommendation on the use of
autologous SCT after rituximab-based salvage therapy.
[Count em] Eleven areas of needed research in the treatment of
follicular lymphoma with SCT were identified and are presented in
Benefits Versus Risks